Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity

Bishnu P. De, Odelya E. Pagovich, Martin J. Hicks, Jonathan B. Rosenberg, Amira Y. Moreno, Kim D. Janda, George F. Koob, Stefan Worgall, Stephen M. Kaminsky, Dolan Sondhi, Ronald Crystal

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Adenovirus (Ad) vaccine vectors have been used for many applications due to the capacity of the Ad capsid proteins to evoke potent immune responses, but these vectors are often ineffective in the context of pre-existing anti-Ad immunity. Leveraging the knowledge that E1-E3- Ad gene transfer vectors are potent immunogens, we have developed a vaccine platform against small molecules by covalently coupling analogs of small molecules to the capsid proteins of disrupted Ad (dAd5). We hypothesized that the dAd5 platform would maintain immunopotency even in the context of anti-Ad neutralizing antibodies. To test this hypothesis, we coupled cocaine and nicotine analogs, GNE and AM1, to dAd5 capsid proteins to generate dAd5GNE and dAd5AM1, respectively. Mice were pre-immunized with Ad5Null, resulting in high titer anti-Ad5 neutralizing antibodies comparable to those observed in the human population. The dAd5GNE and dAd5AM1 vaccines elicited high anti-cocaine and anti-nicotine antibody titers, respectively, in both naive and Ad5-immune mice, and both functioned to prevent cocaine or nicotine from reaching the brain of anti-Ad immune mice. Thus, disrupted Ad5 evokes potent humoral immunity that is effective in the context of pre-existing neutralizing anti-Ad immunity, overcoming a major limitation for current Ad-based vaccines.

Original languageEnglish
Pages (from-to)58-66
Number of pages9
JournalHuman Gene Therapy
Volume24
Issue number1
DOIs
Publication statusPublished - 1 Jan 2013
Externally publishedYes

Fingerprint

Adenovirus Vaccines
Adenoviridae
Immunity
Capsid Proteins
Nicotine
Cocaine
Neutralizing Antibodies
Vaccines
Humoral Immunity
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. / De, Bishnu P.; Pagovich, Odelya E.; Hicks, Martin J.; Rosenberg, Jonathan B.; Moreno, Amira Y.; Janda, Kim D.; Koob, George F.; Worgall, Stefan; Kaminsky, Stephen M.; Sondhi, Dolan; Crystal, Ronald.

In: Human Gene Therapy, Vol. 24, No. 1, 01.01.2013, p. 58-66.

Research output: Contribution to journalArticle

De, BP, Pagovich, OE, Hicks, MJ, Rosenberg, JB, Moreno, AY, Janda, KD, Koob, GF, Worgall, S, Kaminsky, SM, Sondhi, D & Crystal, R 2013, 'Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity', Human Gene Therapy, vol. 24, no. 1, pp. 58-66. https://doi.org/10.1089/hum.2012.163
De, Bishnu P. ; Pagovich, Odelya E. ; Hicks, Martin J. ; Rosenberg, Jonathan B. ; Moreno, Amira Y. ; Janda, Kim D. ; Koob, George F. ; Worgall, Stefan ; Kaminsky, Stephen M. ; Sondhi, Dolan ; Crystal, Ronald. / Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. In: Human Gene Therapy. 2013 ; Vol. 24, No. 1. pp. 58-66.
@article{9d26f25c60ba4afe9f8813d028cb8908,
title = "Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity",
abstract = "Adenovirus (Ad) vaccine vectors have been used for many applications due to the capacity of the Ad capsid proteins to evoke potent immune responses, but these vectors are often ineffective in the context of pre-existing anti-Ad immunity. Leveraging the knowledge that E1-E3- Ad gene transfer vectors are potent immunogens, we have developed a vaccine platform against small molecules by covalently coupling analogs of small molecules to the capsid proteins of disrupted Ad (dAd5). We hypothesized that the dAd5 platform would maintain immunopotency even in the context of anti-Ad neutralizing antibodies. To test this hypothesis, we coupled cocaine and nicotine analogs, GNE and AM1, to dAd5 capsid proteins to generate dAd5GNE and dAd5AM1, respectively. Mice were pre-immunized with Ad5Null, resulting in high titer anti-Ad5 neutralizing antibodies comparable to those observed in the human population. The dAd5GNE and dAd5AM1 vaccines elicited high anti-cocaine and anti-nicotine antibody titers, respectively, in both naive and Ad5-immune mice, and both functioned to prevent cocaine or nicotine from reaching the brain of anti-Ad immune mice. Thus, disrupted Ad5 evokes potent humoral immunity that is effective in the context of pre-existing neutralizing anti-Ad immunity, overcoming a major limitation for current Ad-based vaccines.",
author = "De, {Bishnu P.} and Pagovich, {Odelya E.} and Hicks, {Martin J.} and Rosenberg, {Jonathan B.} and Moreno, {Amira Y.} and Janda, {Kim D.} and Koob, {George F.} and Stefan Worgall and Kaminsky, {Stephen M.} and Dolan Sondhi and Ronald Crystal",
year = "2013",
month = "1",
day = "1",
doi = "10.1089/hum.2012.163",
language = "English",
volume = "24",
pages = "58--66",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity

AU - De, Bishnu P.

AU - Pagovich, Odelya E.

AU - Hicks, Martin J.

AU - Rosenberg, Jonathan B.

AU - Moreno, Amira Y.

AU - Janda, Kim D.

AU - Koob, George F.

AU - Worgall, Stefan

AU - Kaminsky, Stephen M.

AU - Sondhi, Dolan

AU - Crystal, Ronald

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Adenovirus (Ad) vaccine vectors have been used for many applications due to the capacity of the Ad capsid proteins to evoke potent immune responses, but these vectors are often ineffective in the context of pre-existing anti-Ad immunity. Leveraging the knowledge that E1-E3- Ad gene transfer vectors are potent immunogens, we have developed a vaccine platform against small molecules by covalently coupling analogs of small molecules to the capsid proteins of disrupted Ad (dAd5). We hypothesized that the dAd5 platform would maintain immunopotency even in the context of anti-Ad neutralizing antibodies. To test this hypothesis, we coupled cocaine and nicotine analogs, GNE and AM1, to dAd5 capsid proteins to generate dAd5GNE and dAd5AM1, respectively. Mice were pre-immunized with Ad5Null, resulting in high titer anti-Ad5 neutralizing antibodies comparable to those observed in the human population. The dAd5GNE and dAd5AM1 vaccines elicited high anti-cocaine and anti-nicotine antibody titers, respectively, in both naive and Ad5-immune mice, and both functioned to prevent cocaine or nicotine from reaching the brain of anti-Ad immune mice. Thus, disrupted Ad5 evokes potent humoral immunity that is effective in the context of pre-existing neutralizing anti-Ad immunity, overcoming a major limitation for current Ad-based vaccines.

AB - Adenovirus (Ad) vaccine vectors have been used for many applications due to the capacity of the Ad capsid proteins to evoke potent immune responses, but these vectors are often ineffective in the context of pre-existing anti-Ad immunity. Leveraging the knowledge that E1-E3- Ad gene transfer vectors are potent immunogens, we have developed a vaccine platform against small molecules by covalently coupling analogs of small molecules to the capsid proteins of disrupted Ad (dAd5). We hypothesized that the dAd5 platform would maintain immunopotency even in the context of anti-Ad neutralizing antibodies. To test this hypothesis, we coupled cocaine and nicotine analogs, GNE and AM1, to dAd5 capsid proteins to generate dAd5GNE and dAd5AM1, respectively. Mice were pre-immunized with Ad5Null, resulting in high titer anti-Ad5 neutralizing antibodies comparable to those observed in the human population. The dAd5GNE and dAd5AM1 vaccines elicited high anti-cocaine and anti-nicotine antibody titers, respectively, in both naive and Ad5-immune mice, and both functioned to prevent cocaine or nicotine from reaching the brain of anti-Ad immune mice. Thus, disrupted Ad5 evokes potent humoral immunity that is effective in the context of pre-existing neutralizing anti-Ad immunity, overcoming a major limitation for current Ad-based vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84872773039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872773039&partnerID=8YFLogxK

U2 - 10.1089/hum.2012.163

DO - 10.1089/hum.2012.163

M3 - Article

VL - 24

SP - 58

EP - 66

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -